Cargando…

In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester

Photodynamic therapy (PDT) is a well-known method for the treatment of malignant tumors, and its principles have been well established over the past 30 years. This therapy involves the application of a chemical called a photosensitizer and its subsequent excitation with light at the appropriate wave...

Descripción completa

Detalles Bibliográficos
Autores principales: Osiecka, Beata, Jurczyszyn, Kamil, Symonowicz, Krzysztof, Bronowicz, Andrzej, Ostasiewicz, Paweł, Czapińska, Elżbieta, Hotowy, Katarzyna, Krzystek-Korpacka, Małgorzata, Gębarowska, Elżbieta, Iżykowska, Ilona, Dzięgiel, Piotr, Terlecki, Grzegorz, Ziółkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SP Versita 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275856/
https://www.ncbi.nlm.nih.gov/pubmed/20865364
http://dx.doi.org/10.2478/s11658-010-0033-1
_version_ 1783377893992169472
author Osiecka, Beata
Jurczyszyn, Kamil
Symonowicz, Krzysztof
Bronowicz, Andrzej
Ostasiewicz, Paweł
Czapińska, Elżbieta
Hotowy, Katarzyna
Krzystek-Korpacka, Małgorzata
Gębarowska, Elżbieta
Iżykowska, Ilona
Dzięgiel, Piotr
Terlecki, Grzegorz
Ziółkowski, Piotr
author_facet Osiecka, Beata
Jurczyszyn, Kamil
Symonowicz, Krzysztof
Bronowicz, Andrzej
Ostasiewicz, Paweł
Czapińska, Elżbieta
Hotowy, Katarzyna
Krzystek-Korpacka, Małgorzata
Gębarowska, Elżbieta
Iżykowska, Ilona
Dzięgiel, Piotr
Terlecki, Grzegorz
Ziółkowski, Piotr
author_sort Osiecka, Beata
collection PubMed
description Photodynamic therapy (PDT) is a well-known method for the treatment of malignant tumors, and its principles have been well established over the past 30 years. This therapy involves the application of a chemical called a photosensitizer and its subsequent excitation with light at the appropriate wavelength and energy. Topical photodynamic therapy with aminolevulinic acid (5-ALA) is an alternative therapy for many malignant processes, including nonmelanoma skin cancers such as basal-cell carcinoma (BCC). Our novel approach for this study was to use a liposomal formulation of 5-ALA and its methyl ester (commercially available as metvix) both in vitro and in vivo, and to check whether the liposome-entrapped precursors of photosensitizers can induce the expression of metalloproteinases (MMPs) in animal tumor cells and in other tissues from tumor-bearing rats and in selected cell lines in vitro. We also checked whether the application of tissue inhibitors of matrix metalloproteinases (TIMPs) has any effect on MMPs in the above-mentioned experimental models, and if they can cause complete inhibition of MMP expression. Immunohistochemical studies revealed that after the PDT, the intensity of expression of MMPs in healthy animals was very low and seen in single cells only. After the PDT in tumor-bearing rats, MMP-3 was expressed in the tumor cells with the highest intensity of staining in the tissues directly adjacent to the tumors, while MMP-2 and -9 were not found. In the control groups, there was no observed expression of MMPs. In vitro studies showed that MMP-3 was expressed in MCF-7 cells after PDT, but MMP-9 was not observed and MMP-2 was only seen in single cases. Our studies confirmed that the application of an MMP-3 inhibitor may block an induction of MMP-3 expression which had previously been initiated by PDT. The preliminary data obtained from cancer patients revealed that new precursors are effective in terms of PDT, and that using MMP inhibitors should be considered as a potential enhancing factor in clinical PDT.
format Online
Article
Text
id pubmed-6275856
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher SP Versita
record_format MEDLINE/PubMed
spelling pubmed-62758562018-12-10 In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester Osiecka, Beata Jurczyszyn, Kamil Symonowicz, Krzysztof Bronowicz, Andrzej Ostasiewicz, Paweł Czapińska, Elżbieta Hotowy, Katarzyna Krzystek-Korpacka, Małgorzata Gębarowska, Elżbieta Iżykowska, Ilona Dzięgiel, Piotr Terlecki, Grzegorz Ziółkowski, Piotr Cell Mol Biol Lett Research Article Photodynamic therapy (PDT) is a well-known method for the treatment of malignant tumors, and its principles have been well established over the past 30 years. This therapy involves the application of a chemical called a photosensitizer and its subsequent excitation with light at the appropriate wavelength and energy. Topical photodynamic therapy with aminolevulinic acid (5-ALA) is an alternative therapy for many malignant processes, including nonmelanoma skin cancers such as basal-cell carcinoma (BCC). Our novel approach for this study was to use a liposomal formulation of 5-ALA and its methyl ester (commercially available as metvix) both in vitro and in vivo, and to check whether the liposome-entrapped precursors of photosensitizers can induce the expression of metalloproteinases (MMPs) in animal tumor cells and in other tissues from tumor-bearing rats and in selected cell lines in vitro. We also checked whether the application of tissue inhibitors of matrix metalloproteinases (TIMPs) has any effect on MMPs in the above-mentioned experimental models, and if they can cause complete inhibition of MMP expression. Immunohistochemical studies revealed that after the PDT, the intensity of expression of MMPs in healthy animals was very low and seen in single cells only. After the PDT in tumor-bearing rats, MMP-3 was expressed in the tumor cells with the highest intensity of staining in the tissues directly adjacent to the tumors, while MMP-2 and -9 were not found. In the control groups, there was no observed expression of MMPs. In vitro studies showed that MMP-3 was expressed in MCF-7 cells after PDT, but MMP-9 was not observed and MMP-2 was only seen in single cases. Our studies confirmed that the application of an MMP-3 inhibitor may block an induction of MMP-3 expression which had previously been initiated by PDT. The preliminary data obtained from cancer patients revealed that new precursors are effective in terms of PDT, and that using MMP inhibitors should be considered as a potential enhancing factor in clinical PDT. SP Versita 2010-09-17 /pmc/articles/PMC6275856/ /pubmed/20865364 http://dx.doi.org/10.2478/s11658-010-0033-1 Text en © © Versita Warsaw and Springer-Verlag Wien 2010
spellingShingle Research Article
Osiecka, Beata
Jurczyszyn, Kamil
Symonowicz, Krzysztof
Bronowicz, Andrzej
Ostasiewicz, Paweł
Czapińska, Elżbieta
Hotowy, Katarzyna
Krzystek-Korpacka, Małgorzata
Gębarowska, Elżbieta
Iżykowska, Ilona
Dzięgiel, Piotr
Terlecki, Grzegorz
Ziółkowski, Piotr
In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
title In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
title_full In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
title_fullStr In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
title_full_unstemmed In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
title_short In vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
title_sort in vitro and in vivo matrix metalloproteinase expression after photodynamic therapy with a liposomal formulation of aminolevulinic acid and its methyl ester
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275856/
https://www.ncbi.nlm.nih.gov/pubmed/20865364
http://dx.doi.org/10.2478/s11658-010-0033-1
work_keys_str_mv AT osieckabeata invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT jurczyszynkamil invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT symonowiczkrzysztof invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT bronowiczandrzej invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT ostasiewiczpaweł invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT czapinskaelzbieta invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT hotowykatarzyna invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT krzystekkorpackamałgorzata invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT gebarowskaelzbieta invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT izykowskailona invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT dziegielpiotr invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT terleckigrzegorz invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester
AT ziołkowskipiotr invitroandinvivomatrixmetalloproteinaseexpressionafterphotodynamictherapywithaliposomalformulationofaminolevulinicacidanditsmethylester